Hyman: #AACR18 #PrecisionDecision Looking at MSK-IMPACT across 25K pt samples: 10% lvl1; 2% lvl 2A NCCN; 9% more lvl 3A clin trials.

6:10pm April 17th 2018 via Hootsuite